Stem Cells May Be Next Frontier for Diabetes Drugmaker Novo – Bloomberg
Bloomberg |
Stem Cells May Be Next Frontier for Diabetes Drugmaker Novo
Bloomberg Novo's stem cell research may enter clinical trials within five years, Chief Executive Officer Lars Rebien Sorensen said in an interview. The target is a lifelong form of diabetes in which the body's defense system attacks and destroys cells that make … |
